Medmix AG (CHIX:MEDXZ) ROCE %: 2.43% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:MEDXZ Medmix AG CHIX:MEDXZ
66 GF Score
Price CHF8.54
GF Value CHF9.05
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Medmix AG ROCE %?

Medmix AG CHIX:MEDXZ +1.97% 66 ROCE % is 2.43% as of Jun. 2026. GuruFocus rates CHIX:MEDXZ with a GF Score™ of 66/100 and a GF Value™ of CHF9.05 (Fairly Valued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medmix AG's annualized ROCE % for the quarter that ended in Jun. 2026 was 2.43%.

Medmix AG  (CHIX:MEDXz) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medmix AG ROCE % Related Terms

Medmix AG ROCE % Historical Data

* Premium members only.

The historical data trend for Medmix AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medmix AG ROCE % Chart

Medmix AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 7.86 2.20 1.56 0.70 2.50

Medmix AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.09 -1.74 3.56 1.46 2.43
CHIX:MEDXZ
66GF Score
Medmix AG CHIX:MEDXZ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medmix AG ROCE % Calculation

Medmix AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=19.7/( ( (954.2 - 162.9) + (956.4 - 171.9) )/ 2 )
=19.7/( (791.3+784.5)/ 2 )
=19.7/787.9
=2.50 %

Medmix AG's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=19/( ( (956.4 - 171.9) + (970.5 - 188.9) )/ 2 )
=19/( ( 784.5 + 781.6 )/ 2 )
=19/783.05
=2.43 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 2.43% mean?
Medmix AG (CHIX:MEDXZ) has a ROCE % of 2.43% as of Jun. 2026.
Is Medmix AG's ROCE % too high?
Medmix AG's current ROCE % is 2.43%. The Industrial Products industry median ROCE % is 7.09. Medmix AG's value of 2.43% is 65.7% below this industry median. Overall, Medmix AG has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's ROCE % compare to GEV and ETN?
Medmix AG's ROCE % of 2.43% can be compared against companies in the Industrial Products industry. The industry median ROCE % is 7.09. Medmix AG's value of 2.43% is 65.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for an Industrial Products company?
The median ROCE % among Industrial Products companies is 7.09, based on 3,029 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current ROCE % of 2.43% is 65.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Industrial Products industry, the median ROCE % is 7.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current ROCE % is 2.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Based on GuruFocus' analysis, Medmix AG (CHIX:MEDXZ) is currently considered Fairly Valued. The stock's GF Value™ is CHF9.05, compared to a current price of CHF8.54 — trading 5.7% below its estimated fair value. The current ROCE % is 2.43% and 65.7% below the Industrial Products industry median of 7.09. Medmix AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medmix AG (CHIX:MEDXZ), the current ROCE % is 2.43% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medmix AG (CHIX:MEDXZ) Overvalued in 2026?

Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued. The current stock price of CHF8.54 is trading 5.7% below its estimated GF Value™ of CHF9.05. GuruFocus considers Medmix AG to be Fairly Valued.

Key valuation signals for CHIX:MEDXZ:

  • ROCE %: 2.43%
  • GF Value™: CHF9.05 vs. price of CHF8.54 (5.7% below fair value)
  • GF Score™: 66/100 with 6 warning signs
  • Industry Position: 65.7% below the Industrial Products median

No single metric tells the full story. See the CHIX:MEDXZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medmix AG Business Description

Other Exchanges MEDX:Switzerland
Address Neuhofstrasse 20, Baar, CHE, 6340
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
66GF Score

Get the complete analysis for CHIX:MEDXZ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF8.54
Price
CHF9.05
GF Value